Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6126744 | 1.00 | PRCP (0.51) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL205415 | 0.91 | PRCP (0.55) | PRCPOPRM1OPRD1NR1I2ABCB11 | |
| SCHEMBL12175006 | 0.91 | PRCP (0.55) | PRCPOPRM1OPRD1NR1I2ABCB11 | |
| SCHEMBL2708434 | 0.91 | PRCP (0.55) | PRCPOPRM1OPRD1NR1I2ABCB11 | |
| SCHEMBL15430185 | 0.88 | PRCP (0.53) | PRCPOPRM1OPRD1HCRTR1HCRTR2 | |
| SCHEMBL12174996 | 0.87 | PRCP (0.61) | PRCPOPRM1OPRD1NR1I2ABCB11 | |
| SCHEMBL12160053 | 0.87 | PRCP (0.61) | PRCPOPRM1OPRD1NR1I2ABCB11 | |
| SCHEMBL12160098 | 0.87 | PRCP (0.61) | PRCPOPRM1OPRD1NR1I2ABCB11 | |
| SCHEMBL7604141 | 0.87 | PRCP (0.55) | PRCPOPRM1OPRD1NR1I2ABCB11 | |
| SCHEMBL6126817 | 0.87 | PRCP (0.55) | PRCPOPRM1OPRD1NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-24 | — | — | US | disclosed |
| US-9433609-B2 | Benzimidazole-imidazole derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2016-09-06 | — | — | US | disclosed |
| US-9427428-B2 | Benzimidazole-imidazole derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-20140107172-A1 | Benzimidazole-imidazole derivatives | JANSSEN R&D IRELAND (IL) | 2014-04-17 | — | — | US | disclosed |
| US-20120219594-A1 | Benzimidazole-imidazole Derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2012-08-30 | — | — | US | disclosed |
| WO-2011054834-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | TIBOTEC PHARMACEUTICALS (IE) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107172-A1 | Benzimidazole-imidazole derivatives | HAVCR2, CBR3, ZC3HAV1 | PRCP 2221/4885OPRM1 455/4885OPRD1 818/4885 |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | HAVCR2, CBR3, ZC3HAV1 | PRCP 2221/4885OPRM1 455/4885OPRD1 818/4885 |
| US-20120219594-A1 | Benzimidazole-imidazole Derivatives | HAVCR2, CBR3, ZC3HAV1 | PRCP 2221/4885OPRM1 455/4885OPRD1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.